The selected solutions have obtained the Innovation Passport, which gives them access to a mentoring and support pathway to facilitate their entry into the public health system.
The objective of the program is to accelerate the adoption of innovations that provide value to the healthcare system through clinical validation activities, pilot tests, and support in processes of evaluation, procurement, and scalability.
Jorge Fernández, Director of Innovation at Hospital Clínic Barcelona, highlights that “innovation is a strategic axis in the project of the new Clínic-UB Health Campus, conceived as a driving force for transforming healthcare, research, and teaching. The fact that MiWEndo Solutions and Reveal Genomics are two of the four spin-offs stemming from the Clínic Barcelona Comprehensive Cancer Centre reflects our commitment to innovation that generates a real impact on patients.”
Impactful technology focused on clinical practice
MiWEndo Solutions
MiWEndo develops a device that integrates microwave technology into colonoscopy, aiming to improve the detection of polyps and optimize the diagnosis of colon cancer.
Dr. Gloria Fernández, co-founder of MiWEndo Solutions, points out that “this support will allow us to advance in the clinical validation of our technology and demonstrate its real impact on colorectal cancer prevention.”
Reveal Genomics
Reveal Genomics specializes in genomic biomarkers for personalized medicine in cancer, developing diagnostic tests that improve clinical decision-making. The company markets HER2DX, a molecular test for HER2+ breast cancer that predicts the risk of relapse and response to treatments, helping personalize therapy and avoid unnecessary toxicities in this aggressive form of breast cancer that affects about 1,500 women each year in Spain.
Dr. Patricia Villagrasa, CEO and co-founder of Reveal Genomics, states that “the Innovation Passport gives us the boost we need to accelerate the integration of our HER2DX test into the healthcare system and bring precision medicine to a greater number of patients.”
Dr. Aleix Prat, co-founder of the company and Director of the Clínic Barcelona Comprehensive Cancer Centre—a center driven by Clínic, IDIBAPS and UB—adds that “incorporating high-quality genomic data into clinical practice is key to offering more precise and effective treatments. This program will allow us to demonstrate the clinical and organizational impact of HER2DX.”
A program to promote a more efficient, personalized, and accessible healthcare system
The selected initiatives were chosen for their technological maturity and their potential to improve healthcare practice in priority areas such as:
- The transformation of care to make it more efficient, personalized, and proactive.
- The incorporation of clinical and genetic data into therapeutic decision-making.
- The improvement of process management and the reduction of low-value tasks.
- The use of real-time information to anticipate needs and improve patient safety.
The participating companies noted that their main challenge is not technological but rather adoption and scalability, calling for clear pathways to integrate innovation into the Catalan Health System (SISCAT) and ensure equitable access across all regions.
The Innovation Access Program to the Health System of Catalonia (PASS) is led by the Department of Health and Biocat. The initiative collaborates with AQuAS, CatSalut, and Fundació TIC Salut i Social to accelerate the adoption of high-impact innovations in clinical practice, contributing to a more efficient, personalized, and sustainable healthcare system.
